On Jan. 31, 2020, Mammoth Biosciences announced the company had received a contract from the National Institutes of Health (NIH) as part of its $1.5 billion Rapid Acceleration of Diagnostics (RADx) program, making it the first CRISPR based initiative to be funded by the program.

The award helped scale Mammoth Biosciencesﾒ CRISPR-based DETECTR test onto high-throughput automated platforms in commercial labs for COVID-19 diagnostics at an accelerated rate, increasing access to accurate tests with faster turnaround across the country.